1. In order to facilitate the exchange of information on pharmacovigilance within the Community, the Commission, after consulting the Agency, the Each Member States and interested parties, State shall draw up guidelines on the collection, verification and presentation of adverse reaction reports, including technical requirements for electronic exchange of pharmacovigilance information set up and maintain a national medicines web-portal which shall be linked to the European medicines web-portal established in accordance with internationally agreed formats, and shall publish a reference to an internationally agreed medical terminology.
Acting in accordance with the guidelines, marketing authorisation holders Article 26 of Regulation (EC) No 726/2004. By means of the national medicines web-portals, the Member States shall use internationally agreed medical terminology for the reporting of adverse reactions.
These guidelines shall be published in Volume 9 of The Rules governing Medicinal Products in the European Community and shall take account of international harmonisation work carried out in the field of pharmacovigilance.
2. For the interpretation of the definitionsmake publicly available at least the following:
(a) public assessment reports, together with a summary thereof;
(b) summaries of product characteristics and package leaflets;
(c) summaries of risk management plans for medicinal products authorised in accordance with this Directive;
(d) the list of medicinal products referred to in points (11) to (16) of Article 1 and of the principles outlined in this Title, the marketing authorisation holder and the competent authorities shall follow the guidelines Article 23 of Regulation (EC) No 726/2004;
(e) information on the different ways of reporting suspected adverse reactions to medicinal products to national competent authorities by healthcare professionals and patients, including the web-based structured forms referred to in paragraph 1Article 25 of Regulation (EC) No 726/2004.